Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 114 results for "Aggressive B-Cell Lymphoma (ABCL)".

Thumbnail for Primary Central Nervous System Lymphoma in Latin America: Real-World Clinicopathological Characteristics and Survival Outcomes From a National Reference Center

ABCL - 095

Primary Central Nervous System Lymphoma in Latin America: Real-World Clinicopathological Characteristics and Survival Outcomes From a National Reference Center

Amairani Carpintero Diaz

Poster Presenter: Amairani Carpintero Diaz

Thumbnail for Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study

ABCL - 100

Comparative Pharmacovigilance of CD20-Directed Bispecific Antibodies in B-Cell Lymphoma: A FAERS Observational Study

Edward Mwarangu

Poster Presenter: Edward Mwarangu

Previous 1 2 3 4 5...13 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

$Thumbnail for Cellular Kinetics, Efficacy, and Safety of Zamtocabtagene Autoleucel, a Tandem CD20/CD19-Directed CAR T-Cell Therapy, vs R-GemOx in Patients With Relapsed/Refractory LBCL (DALY 2-EU Study)$

ABCL - 1001

Cellular Kinetics, Efficacy, and Safety of Zamtocabtagene Autoleucel, a Tandem CD20/CD19-Directed CAR T-Cell Therapy, vs R-GemOx in Patients With Relapsed/Refractory LBCL (DALY 2-EU Study)

Nirav Shah

Poster Presenter: Nirav Shah

$Thumbnail for Long-Term Outcomes of Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: A Systematic Review of Efficacy, Survival, Minimal Residual Disease, and Safety$

ABCL - 1004

Long-Term Outcomes of Epcoritamab in Relapsed or Refractory Large B-Cell Lymphoma: A Systematic Review of Efficacy, Survival, Minimal Residual Disease, and Safety

Sai Harsha Yendluri

Poster Presenter: Sai Harsha Yendluri

$Thumbnail for Comparative Real-World Efficacy and Safety of 4-1BB-based (Liso-Cel/Tisa-Cel) vs CD28-Construct Containing (Axi-Cel) CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas: A Meta-Analysis$

ABCL - 1011

Comparative Real-World Efficacy and Safety of 4-1BB-based (Liso-Cel/Tisa-Cel) vs CD28-Construct Containing (Axi-Cel) CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas: A Meta-Analysis

Maryam Maqsood

Poster Presenter: Maryam Maqsood

Thumbnail for Projections of Increasing Sex, Geographic, and Age-Based Mortality Disparities in Burkitt Tumor: A Centers for Disease Control and Prevention WONDER Database Analysis Through 2035

ABCL - 1030

Projections of Increasing Sex, Geographic, and Age-Based Mortality Disparities in Burkitt Tumor: A Centers for Disease Control and Prevention WONDER Database Analysis Through 2035

Muhammad Ali Lak

Poster Presenter: Muhammad Ali Lak

Thumbnail for Evaluation of Immune Effector Cell-Associated Neurotoxicity Syndrome Associated With Bispecific Antibodies in Real-World Clinical Use: A Pharmacovigilance Study (2023-2026)

ABCL - 1052

Evaluation of Immune Effector Cell-Associated Neurotoxicity Syndrome Associated With Bispecific Antibodies in Real-World Clinical Use: A Pharmacovigilance Study (2023-2026)

Ashleigh Herbert

Poster Presenter: Ashleigh Herbert

Thumbnail for Phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical activity of the antibody-drug conjugate (ADC) ARC-02 as monotherapy and in combination with rituximab in adults with B-cell non-Hodgkins lymphoma (NHL)

ABCL - 1058

Phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), and clinical activity of the antibody-drug conjugate (ADC) ARC-02 as monotherapy and in combination with rituximab in adults with B-cell non-Hodgkins lymphoma (NHL)

Sinya Okamura

Poster Presenter: Sinya Okamura

Thumbnail for Sex-Based Disparities in Resource Utilization and Complications in Patients Hospitalized with Aggressive B-Cell Non-Hodgkin Lymphoma: A National Inpatient Analysis 2019-2020

ABCL - 1083

Sex-Based Disparities in Resource Utilization and Complications in Patients Hospitalized with Aggressive B-Cell Non-Hodgkin Lymphoma: A National Inpatient Analysis 2019-2020

Aayushi Pareek

Poster Presenter: Aayushi Pareek

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors